Bicyclic heterocycles for selective CB-1 receptor modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for regulating appetite and weight management, particularly involving CB-1 receptor antagonists, face limitations in efficacy and specificity, with potential side effects and limited long-term clinical applicability.
Innovation Solution
Development of compounds according to Formula I, which are pharmaceutical agents that modulate CB-1 receptor activity, potentially used alone or in combination with other therapeutic agents to treat conditions related to appetite regulation and weight management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CB-1 receptor antagonists are used for appetite regulation and weight management, then appetite suppression and weight reduction are achieved, but side effects and limited clinical applicability occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (bicyclic heterocycle core with particular substituent patterns) that target CB-1 receptors with enhanced selectivity. The molecular structure is optimized to interact specifically with the CB-1 receptor binding site, improving therapeutic efficacy while reducing off-target effects and side effects associated with less selective CB-1 antagonists
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and configurations on the bicyclic heterocycle core. These structural parameter modifications allow optimization of receptor binding affinity and selectivity, enabling the development of compounds with improved efficacy-to-side effect ratios compared to existing CB-1 antagonists
2Reliability
If existing CB-1 antagonist treatments are used, then appetite regulation is achieved, but specificity and long-term clinical applicability are limited
Solution Approach 1:
The patent enhances specificity through local quality by incorporating specific functional groups and heteroatom arrangements in the bicyclic heterocycle structure. These localized structural features are designed to match the pharmacophore requirements of the CB-1 receptor with high precision, ensuring selective binding and reducing interactions with other receptor types, thereby improving both specificity and long-term clinical safety
Solution Approach 2:
The patent applies inversion by moving away from the conventional approach of using simple aromatic rings or single-ring heterocycles and instead employing fused bicyclic heterocyclic systems. This structural inversion creates a more rigid and specific binding geometry that enhances receptor selectivity and may improve pharmacokinetic properties for long-term use
Data Source
AI summary
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula:including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.